AndroGel Lawsuit: The Testosterone Litigation

What the Lawsuits Alleged

AndroGel, made by AbbVie, was the best-known of the prescription testosterone gels marketed heavily in the 2010s for “Low T” — a cluster of ordinary symptoms like low energy and reduced libido. More than 6,000 men filed suit, alleging that testosterone-replacement products increased the risk of heart attacks, strokes and blood clots, and that manufacturers promoted the treatment for age-related symptoms without adequate warnings or solid evidence of benefit for that use. The cases were consolidated in a federal multidistrict litigation in Illinois.

The core claim blended a safety theory (cardiovascular risk) with a marketing theory (“disease-mongering” a normal part of aging).

The Verdicts and Settlements

Early bellwether trials produced dramatic but unstable results. Juries returned verdicts of about $150 million and over $140 million against AbbVie — but judges overturned those punitive awards, and one was cut to a few million dollars on retrial. Rather than continue trying cases with such volatile outcomes, AbbVie and other manufacturers moved to resolve the litigation, and by 2018 most claims were settled through global agreements reported to exceed $1 billion in total.

The overturned verdicts are a reminder that a headline jury number is not the same as money paid — post-trial rulings and appeals often reshape the result.

Where Things Stand

The AndroGel testosterone litigation is largely historical: the mass settlements resolved the bulk of the cases years ago, and the FDA has since required labeling that addresses cardiovascular risk and limits approved use. Anyone considering testosterone therapy should discuss the real risks and benefits with a doctor, and be skeptical of marketing that treats normal aging as a condition needing a prescription.